Chronic Rejection Series: Heart Cardiac Allograft Vasculopathy

Area of Science:

• Immunology
• Cardiology
• Transplantation Science

Background:

• Cardiac allograft vasculopathy (CAV) is a primary cause of heart transplant failure, mortality, and morbidity.
• Despite advances, CAV prevalence remains high, necessitating improved management strategies.
• Current treatments focus on prevention and risk factor optimization, with limited novel therapeutic options.

Purpose of the Study:

• To explore the immune mechanisms underlying the initiation and progression of CAV.
• To investigate the role of T cells, antibodies, and other immune factors in CAV development.
• To identify potential targets for novel immune-based therapies for CAV.

Main Methods:

• Review of existing literature on CAV pathogenesis, focusing on immune system involvement.
• Analysis of findings from animal studies elucidating T cell-mediated and other immune responses in CAV.
• Identification of knowledge gaps regarding the translation of animal findings to human CAV.

Main Results:

• Animal studies implicate T cells (alloreactive and autoreactive) and their products in CAV.
• Mechanisms include indirect allorecognition, autoantibodies, bystander T cell activation, and NK cell cooperation.
• The role of interferon-gamma in CAV is also highlighted.

Conclusions:

• CAV involves complex innate and adaptive immune responses, with T cells playing a central role.
• Further research is needed to confirm these immune mechanisms in human CAV patients.
• Understanding these pathways is essential for designing effective immune-based therapies to combat CAV.